Precision Medicine in Oncology®

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Roche has acquired a majority stake in the molecular testing company Foundation Medicine for $1.03 billion, launching a partnership that will focus on the development of personalized medicine for patients with cancer.

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

A lung cancer researcher who has served on the editorial boards of major medical journals, Howard L. "Jack" West, MD, has made communicating with oncology specialists and patients a part of his professional mission.

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

Rituximab dose should be based on age and sex.

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

What patients with cancer perceive as relevant clinical outcomes, and how these outcomes are assessed, is important in the provision of routine care and in the arena of clinical trials.

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.